Cogent Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $234.7M | $242.2M |
| FY2021 | — | $214.2M | $219.7M |
| FY2022 | — | $255.7M | $139.9M |
| FY2023 | — | $257.8M | $53.2M |
| FY2024 | — | $256.3M | $98.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $234.7M | $242.2M |
| FY2021 | — | $214.2M | $219.7M |
| FY2022 | — | $255.7M | $139.9M |
| FY2023 | — | $257.8M | $53.2M |
| FY2024 | — | $256.3M | $98.2M |